3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
4
Phase 2
3
Phase 3
2
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Gynecologic
1
Breast
1
Conditions
Uterine Cervical Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Ovarian Neoplasms
1
Neoplasms by Site
1
Neoplasms
1
Hereditary Sensory and Autonomic Neuropathies
1
Head and Neck Neoplasms
1
Endometrial Neoplasms
1
Breast Neoplasms
1
Breast Diseases
1
Interventions
Trastuzumab
72
Paclitaxel
63
Cyclophosphamide
56
pembrolizumab
52
Fulvestrant
42
Carboplatin
39
Capecitabine
37
Docetaxel
32
Letrozole
27
Doxorubicin
23
palbociclib
21
pertuzumab
20
Nivolumab
18
eribulin
17
abemaciclib
17
ribociclib
16
Gemcitabine
16
130-nm albumin-bound paclitaxel
16
durvalumab
15
Everolimus
15
Albumin-Bound Paclitaxel
15
sacituzumab govitecan
14
Lapatinib
14
Filgrastim
14
fludarabine
13
exemestane
13
Taxes
13
Bevacizumab
13
Cisplatin
12
olaparib
11
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Imlunestrant
×
Breast
×
Clear all
NCT05768139
2026-06-04
PIKALO-1
Eli Lilly and Company
Phase 1/2
Recruiting
880 enrolled